Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Accured Expenses (2019 - 2026)

Immunome filings provide 4 years of Change in Accured Expenses readings, the most recent being -$9.7 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 14.38% to -$9.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.3 million, a 24.13% decrease, with the full-year FY2025 number at $4.5 million, down 66.55% from a year prior.
  • Change in Accured Expenses hit -$9.7 million in Q1 2026 for Immunome, down from $5.7 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.9 million in Q2 2024 to a low of -$9.7 million in Q1 2026.
  • Median Change in Accured Expenses over the past 4 years was $669000.0 (2024), compared with a mean of $688538.5.
  • The widest YoY moves for Change in Accured Expenses: up 13155.81% in 2025, down 1373.69% in 2025.
  • Immunome's Change in Accured Expenses stood at $2.1 million in 2023, then plummeted by 97.92% to $43000.0 in 2024, then skyrocketed by 13155.81% to $5.7 million in 2025, then crashed by 270.98% to -$9.7 million in 2026.
  • The last three reported values for Change in Accured Expenses were -$9.7 million (Q1 2026), $5.7 million (Q4 2025), and $6.7 million (Q3 2025) per Business Quant data.